Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CRDL | 6-K | neutral | 2/10 | Cardiol Therapeutics announced its participation in a fireside chat at the B. Riley Securities Mind, Muscle & Vision Sum | Jul 9, 2026 |
| VERA | 8-K | neutral | 2/10 | Vera Therapeutics announced the transition of Chief Regulatory Officer William Turner to Special Advisor for Regulatory | Jul 9, 2026 |
| MTVA | 8-K | neutral | 3/10 | MetaVia announced that all enrolled active patients in Part 3 of its Phase 1 trial for DA-1726 (obesity) have successful | Jul 9, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a Form 6-K with an Exhibit 99.1 titled 'Application for quotation of securities - ATH'. The | Jul 9, 2026 |
| FBLG | 8-K | neutral | 3/10 | FibroBiologics announced the departure of board member Matt Link and the appointment of Kathleen (Kate) Rubins, Ph.D., a | Jul 9, 2026 |
| AEON | S-1/A | bearish | 6/10 | AEON Biopharma filed Amendment No. 1 to its S-1 registration statement, a procedural exhibits-only update to increase th | Jul 9, 2026 |
| AXSM | COURT-RULING | bullish | 5/10 | Delaware Court of Chancery dismissed with prejudice a stockholder derivative suit against Axsome Therapeutics, ruling th | Jul 9, 2026 |
| GSK | 6-K | neutral | 2/10 | GSK announced the appointment of Roy Jakobs, CEO of Royal Philips, as an independent Non-Executive Director effective Ju | Jul 9, 2026 |
| VRAX | 6-K | bullish | 5/10 | Virax Biolabs announced an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSele | Jul 9, 2026 |
| INMB | PRESS-RELEASE | bullish | 5/10 | INmune Bio announced new Phase 2 imaging data for XPro1595 in early Alzheimer's disease, showing statistically significa | Jul 9, 2026 |
| CSTL | PRESS-RELEASE | neutral | 1/10 | Castle Biosciences, Inc. announced it will report its Q2 2026 results on July 30, 2026. | Jul 9, 2026 |
| KYTX | 8-K | neutral | 4/10 | Kyverna Therapeutics amended its existing loan facility with Oxford Finance LLC to extend availability of the remaining | Jul 9, 2026 |
| RKDA | EFFECT | bearish | 6/10 | Arcadia Biosciences' shelf registration (File No. 333-297072) became effective on July 8, 2026, enabling the resale of u | Jul 9, 2026 |
| AQST | EFFECT | neutral | 5/10 | Aquestive Therapeutics' S-3 shelf registration (333-297069) became effective on July 8, 2026, allowing the company to of | Jul 9, 2026 |
| KRRO | INST-CLUSTER | bullish | 6/10 | In Q1 2026, 11 institutional investors accumulated $18.0M in KRRO (net +$16.6M) while 6 reduced holdings by $1.7M. Balya | Jul 9, 2026 |
| NUVL | CLUSTER | neutral | 3/10 | Three top executives at Nuvalent (CEO, CFO, CDO) sold a combined $7.97M in open-market sales over a 7-day window, with t | Jul 9, 2026 |
| CADL | CLUSTER | neutral | 3/10 | Two C-suite insiders at Candel Therapeutics sold $306K in open-market sales on June 29, 2026, while a third insider rece | Jul 9, 2026 |
| RLAY | CLUSTER | neutral | 2/10 | Two insiders at Relay Therapeutics sold a combined $1.12M in stock over a one-week window, including a $955K sale by Pet | Jul 9, 2026 |
| MIRM | CLUSTER | neutral | 2/10 | Two Mirum Pharmaceuticals insiders (CFO Eric Bjerklholt and SVP/Global Controller Jolanda Howe) sold a combined $707K in | Jul 9, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt sold ~$10.4M in open-market shares over two days (0.04% of market cap), alongside derivative exerc | Jul 9, 2026 |
| PTCT | CLUSTER | neutral | 2/10 | Two C-suite insiders (CTOO and EVP/CLO) sold a total of ~$2.6M in shares on July 6-7, 2026, predominantly tied to option | Jul 9, 2026 |
| PBYI | CLUSTER | neutral | 2/10 | Two PBYI insiders, including the CFO, sold a combined $147K in open-market sales over a 7-day window. The total value is | Jul 8, 2026 |
| BOLD | CLUSTER | neutral | 4/10 | Three 10% owners at Boundless Bio traded in opposing directions within a 7-day window: Kevin Tang (10% owner) purchased | Jul 8, 2026 |
| CORT | CLUSTER | neutral | 3/10 | Two Corcept insiders sold shares totaling ~$2.77M over a 7-day window, with the Chief Development Officer selling after | Jul 8, 2026 |
| XNCR | CLUSTER | neutral | 2/10 | Four Xencor Inc directors sold shares totaling $290K on June 15, 2026, all at $12.31 per share. The cluster represents o | Jul 8, 2026 |
| PALI | CLUSTER | neutral | 3/10 | Insider trading cluster at PALISADE BIO shows CEO/CFO John David Finley selling $303K in open-market shares, while Direc | Jul 8, 2026 |
| CTNM | CLUSTER | neutral | 2/10 | Two C-suite insiders at Contineum Therapeutics (CEO and CSO) sold a combined $132K in open-market sales over a 7-day win | Jul 8, 2026 |
| AMGN | COURT-RULING | bearish | 4/10 | The court granted in part Regeneron's motion to strike Amgen's inequitable conduct, antitrust, patent misuse, and unclea | Jul 8, 2026 |
| CPRX | 8-K | bullish | 6/10 | Catalyst Pharmaceuticals stockholders approved the $31.50/share all-cash acquisition by Angelini Pharma at the July 8, 2 | Jul 8, 2026 |
| REGN | COURT-RULING | bullish | 6/10 | Regeneron won a significant motion in its patent infringement litigation against Amgen, with the court striking Amgen's | Jul 8, 2026 |